PODD logo

PODD
Insulet Corporation

1,962
Mkt Cap
$10.73B
Volume
1.3M
52W High
$354.88
52W Low
$145.59
PE Ratio
35.80
PODD Fundamentals
Price
$153.80
Prev Close
$154.87
Open
$154.88
50D MA
$188.33
Beta
0.85
Avg. Volume
1.08M
EPS (Annual)
$3.48
P/B
8.18
Rev/Employee
$501,500.00
$20,718.68
Loading...
Loading...
News
all
press releases
Insulet Initiates Voluntary Medical Device Correction for Certain Omnipod Pods in the U.S. and Affected International Markets
Insulet Corporation, Inc. (NASDAQ: PODD) (Insulet or the Company) today announced a voluntary Medical Device Correction for specific lots of Omnipod 5, Omnipod DASH, and Omnipod Insulin Management System (Omnipod Eros) Pods due to a manufacturing issue, identified through ongoing product...
News Placeholder
More News
News Placeholder
Here's Why Insulet (PODD) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
News Placeholder
Why Insulet (PODD) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
News Placeholder
Abbott's Medical Device Strategy Supports Long-Term Growth Outlook
ABT's Medical Devices segment posts 8.5% Q1 growth as Electrophysiology, Rhythm Management and Heart Failure deliver strong gains.
News Placeholder
Insulet (NASDAQ:PODD) Posts Quarterly Earnings Results, Beats Estimates By $0.23 EPS
Insulet (NASDAQ:PODD - Get Free Report) announced its quarterly earnings data on Wednesday. The medical instruments supplier reported $1.42 earnings per share (EPS) for the quarter, topping the...
News Placeholder
Insulet Q1 Earnings Call Highlights
Insulet (NASDAQ:PODD) reported what executives described as a "strong start" to fiscal 2026, posting double-digit revenue growth in the first quarter while expanding operating margins and raising its full-year revenue outlook. First-quarter results and raised full-year revenue guidance President an...
News Placeholder
Insulet (NASDAQ:PODD) Hits New 52-Week Low Following Analyst Downgrade
Insulet (NASDAQ:PODD) Reaches New 1-Year Low on Analyst Downgrade...
News Placeholder
BTIG Research Issues Pessimistic Forecast for Insulet (NASDAQ:PODD) Stock Price
BTIG Research cut their target price on shares of Insulet from $320.00 to $260.00 and set a "buy" rating on the stock in a research note on Wednesday...
News Placeholder
Insulet (PODD) Loses 17.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Insulet (PODD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
News Placeholder
Insulet (PODD) Q1 Earnings and Revenues Top Estimates
Insulet (PODD) delivered earnings and revenue surprises of +24.84% and +4.60%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available